Bayern Munich midfielder Jamal Musiala suffered two on‑pitch collapses within four days during pre‑season friendlies; both the player and the club have said the episodes are brief, treatable absence seizures caused by a neurological dysfunction and that a recent change to his medication produced side‑effects.
- Musiala collapsed twice in four days during pre‑season; both Bayern and the player say these were absence seizures caused by a neurological dysfunction.
- Bayern say a recent slight change to Musiala’s medication produced side‑effects linked to the episodes; the precise medication change has not been disclosed.
- Specialists have reportedly cleared Musiala to continue playing under supervision, and the player has expressed optimism and asked for privacy over treatment details.
- No public clinical test results or drug names have been published; further medical monitoring will determine his availability for competitive matches.
What has been confirmed so far
Sources close to the player and Bayern confirm the sequence of events: Musiala went down during a friendly against RB Leipzig and then again four days later in a match with Heidenheim. The incidents were visible to team‑mates and medical staff and led to on‑pitch treatment and his removal from the field.
Bayern head coach Vincent Kompany told reporters the player had made a “slight” change to his treatment and that this had led to side‑effects surrounding the two collapses. Musiala has posted on social media saying he has been diagnosed with “brief, temporary but treatable” absence seizures resulting from a neurological dysfunction, and that specialists have cleared him to continue playing while receiving treatment.
Medical explanation in the coverage
Reporting by major outlets and medical commentary included in coverage explains absence seizures as short lapses in awareness — typically lasting only a few seconds — which can present as staring spells, a temporary loss of balance or apparent unresponsiveness. Neurologists quoted in the coverage said such seizures are often treatable with medication and, when managed, are not necessarily incompatible with high‑level sport.
What the club and player have said
Bayern sporting director Max Eberl and club representatives have told the public the club were aware of signs of the condition before the World Cup and that medical specialists had provided written clearance about Musiala taking part in high‑performance sport. Kompany said Musiala would train individually in the short term while the team prepares for the German Supercup against Borussia Dortmund.
Musiala’s own statement, published on his social account and reproduced in reporting, said he is optimistic, receiving specialist care, and that “there is no additional health risk beyond this.” He also requested that details of his treatment remain private between himself, his family, the club and medical experts.
Where reporting differs — and what is not yet public
- All available coverage agrees on the collapses, Musiala’s diagnosis as absence seizures, and that he and Bayern are handling the case with medical oversight.
- Not all outlets provide the same level of clinical detail. Some quoted neurologists who said the episodes could represent a form of epilepsy that may require long‑term therapy, while others emphasised the condition is commonly manageable and that triggers (for athletes) can include dehydration and hyperventilation. Those expert comments noted that definitive judgements require full neurological test results, which have not been made public.
- No source in the packet provides independent confirmation of the precise medication changed, its name, dosage, or the specific side‑effects observed; Bayern and Kompany described the change only as “slight.”
Why this matters for Bayern and the Supercup
Musiala is a central creative figure for Bayern; his availability affects squad selection, tactical planning and rotation for the early season fixtures. Kompany has already indicated Musiala will train separately this week, and the club ruled him out of the Supercup squad alongside two other players, according to reporting. Whether he will feature in competitive games depends on ongoing specialist advice and how he responds to treatment.
Practical implications and next steps
- Medical follow‑up: Expect further neurological assessment and monitoring. Outlets note specialists have so far cleared him to play, but that ongoing review is typical when treatment is adjusted.
- Training management: Bayern have said Musiala will do individual sessions. Clubs commonly limit exposure to match intensity while symptoms and medication side‑effects are assessed.
- Fixture availability: Selection for the Supercup and the early Bundesliga rounds will be decided case‑by‑case in consultation with medical staff; no independent confirmation of definitive availability has been published yet.
- Privacy and communication: Musiala has asked for treatment details to remain private; the club has said it will continue to support him and work with specialists.
Context: Musiala’s recent injury history
Reporting reminds readers this follows a turbulent period for Musiala. He missed large parts of the previous season with a serious leg and ankle injury that required surgery and the use of a metal plate, which was removed in July. He returned to international duty at the World Cup earlier this summer. Those recent injuries are factual background in media coverage but no outlet connects them causally to the current neurological diagnosis.
Timeline of recent events
- Prior to the World Cup: Club sources said there were signs of the condition, though it had not visibly affected him on the pitch for Bayern.
- Saturday (pre‑season friendly): Musiala collapsed late in the match against RB Leipzig; medical staff attended and he was cleared to continue activity pending tests reported to club specialists.
- Four days later (pre‑season friendly): Musiala collapsed again against Heidenheim shortly after coming on; again he received on‑field treatment and left the pitch.
- Following the second collapse: Musiala posted that he has treatable absence seizures, and Bayern officials, including Kompany and Eberl, said a slight medication change had produced side‑effects; specialists have been involved in decisions about his care.
What to watch for next
Supporters should look for official bulletins from Bayern or statements from Musiala confirming any change to his playing status. Reliable indicators to follow are confirmation of clinician sign‑off for match participation, details that medics choose to share about monitoring or modified treatment plans, and whether Musiala resumes team training sessions rather than individual work.
Bottom line
Reporting from Bayern and the player presents a consistent immediate picture: Musiala has been diagnosed with brief, treatable absence seizures tied to a neurological dysfunction; a recent alteration to his medication appears to have produced side‑effects linked to two collapses within four days. Specialists have been consulted and, according to the club and player, have cleared him to continue under supervision. Public coverage lacks detailed clinical data — including the exact medication change or full test results — so clinicians’ longer‑term assessments and selection decisions will determine the practical impact on Bayern’s season.
“I have been diagnosed with brief, temporary but treatable absences (absence seizures) caused by a neurological dysfunction.”